Mesalizine-Induced Acute Pancreatitis and Interstitial Pneumonitis in a Patient with Ulcerative Colitis
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Ulcerative colitis (UC) is a chronic idiopathic inflammatory bowel disease. Mesalizine for the first-line therapy of UC has adverse effects include pancreatitis, pneumonia and pericarditis. UC complicated by two coexisting conditions, however, is very rare. Moreover, drug-related pulmonary toxicity is particularly rare. An 11-year-old male patient was hospitalized for recurring upper abdominal pain after meals with vomiting, hematochezia and exertional dyspnea developing at 2 weeks of mesalizine therapy for UC. The serum level of lipase was elevated. Chest X-ray and thorax computed tomography showed interstitial pneumonitis. Mesalizine was discontinued and steroid therapy was initiated. Five days after admission, symptoms were resolved and mesalizine was resumed after a drop in amylase and lipase level. Symptoms returned the following day, however, accompanied by increased the serum levels of amylase and lipase. Mesalizine was discontinued again and recurring symptoms rapidly improved.
Abstract
Ulcerative colitis (UC) is a chronic idiopathic inflammatory bowel disease. Mesalizine for the first-line therapy of UC has adverse effects include pancreatitis, pneumonia and pericarditis. UC complicated by two coexisting conditions, however, is very rare. Moreover, drug-related pulmonary toxicity is particularly rare. An 11-year-old male patient was hospitalized for recurring upper abdominal pain after meals with vomiting, hematochezia and exertional dyspnea developing at 2 weeks of mesalizine therapy for UC. The serum level of lipase was elevated. Chest X-ray and thorax computed tomography showed interstitial pneumonitis. Mesalizine was discontinued and steroid therapy was initiated. Five days after admission, symptoms were resolved and mesalizine was resumed after a drop in amylase and lipase level. Symptoms returned the following day, however, accompanied by increased the serum levels of amylase and lipase. Mesalizine was discontinued again and recurring symptoms rapidly improved.
참고문헌 (19)
- 한동수, "다량의 복수가 주 증상으로 나타난 POEMS 증후군 1예", 대한소화기학회지, 40(3), pp.1~1 (2002), 대한소화기학회
- Seo JK, "Inflammatory bowel disease in children--clinical, endoscopic, radiologic and histopathologic investigation", J Korean Med Sci, 7, pp.221~235 (1992)
- Xavier RJ, "Unravelling the pathogenesis of inflammatory bowel disease", Nature, 448, pp.427~434 (2007)
- Ransford RA, "Sulphasalazine and mesalazine:serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines", Gut, 51, pp.536~539 (2002)
- Candy S, "A controlled double blind study of azathioprine in the management of Crohn's disease", Gut, 37, pp.674~678 (1995)
- Williams T, "Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy", Chest, 81, pp.766~768 (1982)
- Fardy JM, "Adverse effects with oral 5-aminosalicyclic acid", J Clin Gastroenterol, 10, pp.635~637 (1988)
- Toubanakis C, "Acute pancreatitis after long-term therapy with mesalazine, and hyperamylasaemia associated with azathioprine in a patient with ulcerative colitis", Eur J Gastroenterol Hepatol, 15, pp.933~934 (2003)
- Woltsche M, "Sulfasalazine-induced extrinsic allergic alveolitis in a patient with psoriatic arthritis", Eur J Med Res, 6, pp.495~497 (2001)
- Chikano S, "Interstitial pneumonia accompanying ulcerative colitis", Intern Med, 40, pp.883~886 (2001)
- Herrlinger KR, "The pancreas and inflammatory bowel diseases", Int J Pancreatol, 27, pp.171~179 (2000)
- Fiorentini MT, "Acute pancreatitis during oral 5-aminosalicylic acid therapy", Dig Dis Sci, 35, pp.1180~1182 (1990)
- Lankisch PG, "Drug induced acute pancreatitis: incidence and severity", Gut, 37, pp.565~567 (1995)
- Balani AR, "Drug-induced pancreatitis :incidence, management and prevention", Drug Saf, 31, pp.823~837 (2008)
- Castiglione F, "Prevention of pancreatitis by weekly amylase assay in patients with Crohn's disease treated with azathioprine", Am J Gastroenterol, 95, pp.2394~2395 (2000)
- Foster RA, "Mesalamine-related lung disease: clinical, radiographic, and pathologic manifestations", Inflamm Bowel Dis, 9, pp.308~315 (2003)
- Camus P, "The lung in inflammatory bowel disease", Medicine (Baltimore), 72, pp.151~183 (1993)
- Rothfuss KS, "Extraintestinal manifestations and complications in inflammatory bowel diseases", World J Gastroenterol, 12, pp.4819~4831 (2006)
- Rutgeerts P, "Infliximab for induction and maintenance therapy for ulcerative colitis", N Engl J Med, 353, pp.2462~2476 (2005)